Navigation Links
Xenon Exclusively Licenses to Merck Compounds for a Novel Target for Cardiovascular Disease
Date:4/17/2013

VANCOUVER, British Columbia, April 17, 2013 /PRNewswire/ -- Xenon announced that Merck, known as MSD outside the United States and Canada, through an affiliate, has exercised its option to exclusively license small molecule compounds for a novel target for the potential treatment of cardiovascular disease. In 2009, Xenon and Merck entered into a strategic alliance where Xenon employed its human clinical genetics platform to validate novel cardiovascular targets and collaborated on the discovery and development of small molecule compounds for those targets.

"We are very pleased that Merck has exercised this option to license novel discoveries from the collaboration," said Simon Pimstone , President and CEO of Xenon. "The discovery of loss-of-function mutations for this target in humans with protective cardiovascular profiles was central for the development of compound modulators of the target."

Under the terms of the 2009 agreement, Xenon received milestone payments and an option fee and is eligible for further research, development and regulatory milestone payments of up to US$86.5 million. In addition, Merck will pay Xenon undisclosed royalties on sales of products resulting from the collaboration.

About Xenon Pharmaceuticals Inc. (Xenon)
Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing novel therapies for rare diseases. For more information, visit the Company's website at http://www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Xenon Announces Appointment of EVP, Research & Development
2. Xenon Named Life Sciences Company of the Year by LifeSciences British Columbia
3. Validus Pharmaceuticals Now Exclusively Marketing Six Established U.S. Product Lines Purchased From Leading Healthcare Company
4. Vicks Starry Night Humidifier Available Now in New Colors Exclusively at Babies"R"Us
5. MetaStat, Inc. Executes Two New Licenses
6. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
7. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
8. NTT DATA Licenses DATATRAK ONE™ for China
9. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
10. West Health Institute licenses Kinect-based physical therapy technology to Reflexion Health; West Health Investment Fund makes $4.25 million investment
11. Parios Regenerative Sciences, Inc. Licenses Exclusive Rights to Organic Nanotechnology for Skin Repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... 8, 2017 ... Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 th .The ... free MRI brain scans to the public.Where:  BTF,s ... at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the ...
(Date:9/7/2017)... Texas , Sept. 7, 2017 ... science focused on fulfilling the promise of precision ... further validate the benefits of its molecular profiling ... study utilized comprehensive genomic profiling plus (CGP+) with ... individual patient,s tumor on a molecular level, leading ...
(Date:9/6/2017)... TORONTO , Sept. 6, 2017 /PRNewswire/ ... new knowledge and skills while treating their ... for hands-on experience without involving patients. Simulation ... skills. Clinicians can carry out procedures, refine ... at risk. Integration of new technology, such ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... With ProSlideshow Portrait from ... easy to do. Users can select from up to two layers of subject matter ... of a mouse all within Final Cut Pro X. , With ProSlideshow ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, ... http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and device marketing and ... compliance with FDA rules. , The FDA has issued two draft guidances that ...
(Date:9/21/2017)... ... 2017 , ... Innovatum will demonstrate capabilities of fully automated ... 2017 in Chicago, IL on October 17-19, 2017. This unique development addresses the ... safety. , Microscan , a global technology leader in barcoding, machine ...
(Date:9/21/2017)... ... , ... FlipBelt, the fitness brand that specializes in problem solving fitness accessories, ... with the launch of their FlipBelt Crops. , The new fitness bottoms feature an ... while at the gym, on the trail, or on-the-go. , “We always thought the ...
(Date:9/20/2017)... ... September 20, 2017 , ... FirstAlign ( http://www.firstalign.com ), ... latest Artificial Intelligence (AI) thinking, announced today the launch of its revamped web ... essential information that offers a more comprehensive understanding of the organization’s business and ...
Breaking Medicine News(10 mins):